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Abstract. The exact molecular background and the connection between protein and mRNA expression in colorectal cancer (CRC)
development and progression are not completely elucidated. Our purposes were the identification of protein markers of colorectal
carcinogenesis and progression using protein arrays and validation on tissue microarrays. The connection between antibody and
mRNA expression array results was also examined. Using cancerous and adjacent normal samples from 10 patients with early
and 6 with advanced CRC, 67 differentially expressed genes were identified between normal and cancerous samples. A marker
set containing 6 proteins (CCNA1, AR, TOP1, TGFB, HSP60, ERK1) was developed which could differentiate normal specimen,
early and late stage CRC with high sensitivity and specificity. Dukes D stage samples were analyzed on HGU133plus2.0
microarrays. In these samples, mRNA and protein expression of 143 genes showed strong positive correlations (R2 > 0.8), while
a negative correlation (R2 > 0.9) was found in case of 95 genes. Based on our results a correlation could be established between
transcriptome and antibody array results, hence the former may be used as a high-capacity screening method before applying
antibody arrays containing already planned targets. Antibody microarrays may have a fundamental importance in testing of
marker combinations and future application in diagnostics of tumorous diseases.
Keywords: Colorectal cancer, progression marker, antibody microarray, gene expression, transcriptomics, proteomics, bioequiv-
alency
1. Introduction
Colorectal cancer (CRC) is the second most fre-
quent cause of tumor related death in Western coun-
tries [1,2]. In the molecular biological background of
CRC, different genetic pathways are known to be de-
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fected: changes in DNA like SNP, insertion, deletion,
duplication, methylation, on the other hand changes
of the regulation of transcription and translation such
as splicing, miRNAs, phosphorylation, glycosylation,
complex formation and different interactions [3–11].
One of the best known pathways is the adenoma-
dysplasia-carcinoma sequence, in which dysplastic
crypts develop from normal epithelium after APC mu-
tation, followed by an adenoma. During the process,
chromosomal instability and aneuploidy may also be
present [11–13]. Chromosomal or microsatellite insta-
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bility and the presence or absence of CpG island methy-
lator phenotype establish the basis of molecular patho-
logical classification. These characteristics may be used
successfully during the examination of left and right
sided colon tumours or when selecting a chemother-
apy protocol [1,2,14]. However, the association be-
tween these molecular events and protein expression
alterations has not yet been clarified.
Whole genomic arrays provide an excellent oppor-
tunity for the development of molecular expression
pattern based colorectal cancer classification [3,7,10].
The diagnostic application of these patterns has al-
so emerged as a possibility [15–18] according to the
results of our research team. Using array technolo-
gies, the discrimination of early and late stage colorec-
tal cancers [14], the prediction of metastatic and non-
metastatic disease [19] as well as the characterization
of the adenoma-dysplasia-carcinoma sequence became
possible [20,21].
Array techniques can also be used for the protein
level based description of molecular changes leading
to tumour development [15]. In recent years, besides
conventional MS and 2D elfo techniques, protein chips
have become available. This technology results not just
in qualitative expression patterns, but may also be used
to determine the quantity of the examined protein. An
additional advantage of protein arrays is their easier
sample preparation compared to the other two classical
proteomics technologies.
The molecular changes that lead to cancer develop-
ment may be explored by using several techniques at
mRNA and protein level, however the connections be-
tween these levels are not fully understood. The lack of
permeability between technological platforms hinders
the comparison of results. Array techniques allow us
to perform mRNA and protein analysis from the same
samples, hence the discovery of the coherence between
results may become closer.
Regarding the correlation between protein and
mRNA expression chips, there are no definite litera-
ture data, not even from cell culture studies. In yeast,
the detection of protein and mRNA profile similari-
ties failed [22]. This may be explained by the time
frame between transcription and translation, the mRNA
processing, the half-life time and degradation of these
macromolecules. To our knowledge, there are hard-
ly any published studies focusing on the associations
between mRNA and protein levels, which may be im-
portant in case of tumorous diseases, using only mi-
croarray techniques. There are already a few data avail-
able from transcript profile analyses that were simul-
taneously prepared using protein level MS, bead-array,
and ELISA examinations. Previously, a positive corre-
lation of 32 percent was reported by the parallel analy-
sis of 1200 proteins and transcripts [23].
In this study we examined how the changes at
mRNA level, modified during disease development and
progression, influence protein expression, and whether
these altered protein expression patterns may be used
for the molecular classification of colorectal cancer
(Fig. 1).
2. Materials and methods
2.1. Sample collection
Surgically removed tissue samples from the diseased
and the healthy parts of the colon of 16 colorectal cancer
patients (10 Dukes B, 6 Dukes D stage, Table 1.) were
collected. Maximum 10 minutes after resection 500 mg
tissue were snap frozen in liquid nitrogen both from the
intact mucosa, close to the resection line and from the
tumorous tissue. Samples were then stored at −80◦C.
In parallel, formalin fixed, paraffin embedded tissue
samples were also prepared from the same samples
for both conventional histopathological diagnosis and
tissue microarrays.
2.2. Protein isolation
Frozen samples were homogenised in lysis buffer,
then 1 g of Alumina (Sigma Aldrich) was added to each
gramm of initial material. After extensive homogenisa-
tion, samples were centrifuged at 25000 g for 10 min-
utes. The supernatant containing the crude extract was
stored in 100 µl aliquots at −80◦C until utilization.
2.3. Clontech AB 500 array analysis
The protein concentrations of the crude extracts were
measured with the BCA method. 1 mg/ml working
solutions were prepared from all samples. Cy3 and
Cy5 monoreactive dyes were used for protein labelling
according to the manufacturer’s description (Amer-
sham/GE Healthcare). Labelling was carried out with
the dye swap method. In reaction A, the tumorous
sample was labelled with Cy5 (red), and the normal
sample with Cy3 (green). Afterwards, in reaction B,
the tumorous sample was labelled with Cy3 and the
normal sample with Cy5. Labelled protein cleaning
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Fig. 1. Depicting of study design. Part A represents the analysis process of Dukes B stage colorectal cancer samples. Fresh frozen surgical tissue
samples from tumorous and healthy colonic region of 10 CRC patients were analyzed on antibody arrays. TMA validation was performed on
an extended set of 20 tumorous and 12 healthy FFPE samples. Part B shows preparation procedure of 6 Dukes D stage samples. Similarly to
the early stage sample analysis, protein expression profiling was done on both protein arrays and TMAs. Furthermore, whole genomic mRNA
expression pattern was determined by Affymetrix HGU 133 Plus 2.0 microarrays in order to examine the associations between transcriptome and
proteome.
and the removal of redundant dyes were performed on
a CD10 column (Amersham/GE Healthcare).
The concentrations of the labelled and cleaned pro-
teins were also measured with the BCA method. Next,
equivalent amounts of differently labelled proteins
(100–100 µg from each variant) were mixed. The
hybridization mix was prepared by using 30 µg of the
mixture. The hybridization was performed on Clontech
AB 500 (Clontech) arrays according to the manufac-
turer’s description, then the arrays were washed with
absolute ethanol to remove non-binding material. Af-
ter drying centrifugation, protein arrays were stored in
dark until scanning.
Scanning was carried out on an Axon 4000B scan-
ner (Axon Instruments, USA) at 532 and 635 nm
wavelengths. Array analysis was performed using the
GenePix 4.1 software at 33 percent laser force, 560
and 670 PMT gain, and 20 m/pixel resolution. Af-
ter placing the array net (Lot: 5010317), fluorescence
and background intensities were determined on both
channels. Then a local background correction was per-
formed. Data were exported in gpr and csv formats.
Data analysis was carried out using the R-environment.
After processing (RMA, normexp), array results were
normalized with the quantile method.
The identification of genes with expression differ-
ence was performed by using the normalized M val-
ues / M = log2(R/G); R: red fluorescence intensity, G:
green fluorescence intensity/.
The limit of significant difference in case of protein
markers is at M =± 0.5 which represents an alteration
in expression of at least 30 percent.
2.4. Tissue microarray analysis
The results of the protein array analysis were vali-
dated by TMA on an extended set of samples. Apart
from 15 healthy tissue samples, 36 colorectal cancer
specimen from different localizations, grade of differ-
entiation and Dukes stage were included in the val-
idation process. Cores of 2 mm diameter were col-
lected and placed together into 24 samples recipi-
ent blocks. Five µm thick tissue sections were cut
from the TMA blocks, mounted on adhesive glass
slides and immunostained following endogenous hy-
drogen peroxidase blocking (0.5% H2O2-methanol)
and heat-induced epitope retrieval in 150 ml of pH
6.0 TRS buffer (Target Retrieval Solution, S1699) us-
ing a commercial microwave oven at 300 W power
for 45 minutes. The following immunohistochemistries
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Table 1
Patient and histological data
Sample ID Age Sex Localization Dukes stage Histology, differentiation Antibody array Affymetrix TMA
CRC
5 80 F rectum B well differentiated adenocarcinoma + +
8 58 F sigma D moderately differentiated adenocarcinoma + + +
11 66 M sigma B moderately differentiated adenocarcinoma + +
12 56 F sigma D moderately differentiated adenocarcinoma + + +
13 69 M sigma D poorly differentiated adenocarcinoma + + +
15 72 M rectum D poorly differentiated adenocarcinoma + + +
16 82 M rectum B moderately differentiated adenocarcinoma + +
18 55 M rectum B well differentiated adenocarcinoma + +
20 62 M rectum B moderately differentiated adenocarcinoma + +
22 64 F sigma B well differentiated adenocarcinoma + +
31 52 M rectum B well differentiated adenocarcinoma + +
32 59 F rectum B moderately differentiated adenocarcinoma + +
33 70 F rectum D moderately differentiated adenocarcinoma + + +
39 62 M sigma D poorly differentiated adenocarcinoma + + +
45 59 M sigma B well differentiated adenocarcinoma + +
46 83 M rectum B moderately differentiated adenocarcinoma + +
49 56 M rectum D moderately differentiated adenocarcinoma +
50 69 M rectum D poorly differentiated adenocarcinoma +
56 63 M rectum B poorly differentiated adenocarcinoma +
58 72 F sigma B poorly differentiated adenocarcinoma +
61 58 M sigma B moderately differentiated adenocarcinoma +
64 73 M sigma D poorly differentiated adenocarcinoma +
66 67 M sigma B moderately differentiated adenocarcinoma +
69 57 F rectum B well differentiated adenocarcinoma +
70 64 F sigma B moderately differentiated adenocarcinoma +
74 74 M sigma D poorly differentiated adenocarcinoma +
78 68 F rectum B poorly differentiated adenocarcinoma +
86 82 M rectum B well differentiated adenocarcinoma +
91 79 M rectum D moderately differentiated adenocarcinoma +
94 84 M rectum D moderately differentiated adenocarcinoma +
97 56 F sigma B poorly differentiated adenocarcinoma +
100 62 M sigma D poorly differentiated adenocarcinoma +
110 75 M rectum B well differentiated adenocarcinoma +
115 65 F sigma D poorly differentiated adenocarcinoma +
Normal
5 80 F rectum normal + + +
8 58 F sigma normal + +
11 66 M sigma normal + + +
12 56 F sigma normal + + +
13 69 M sigma normal + + +
15 72 M rectum normal + +
16 82 M rectum normal + +
18 55 M rectum normal + +
20 62 M rectum normal + +
22 64 F sigma normal + +
31 52 M rectum normal + +
32 59 F rectum normal + + +
33 70 F rectum normal + + +
39 62 M sigma normal + +
45 59 M sigma normal + +
46 83 M rectum normal + +
49 56 M rectum normal +
50 69 M rectum normal +
56 63 M rectum normal +
58 72 F sigma normal +
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were performed: APC, Caveolin, CBP, cyclinA, ERK,
HSP60, Cox2, EGFR, C-myc, Cald, Top1, DARPP32,
MRE11A, AndrogenR, EPS8.
Immunostained TMA slides and blood smears were
digitalized using a high-resolution Mirax Desk instru-
ment (Zeiss, Goettingen, Germany) and the stained
spots were analysed with the Mirax TMA Module soft-
ware (Zeiss). Protein expression was evaluated using
an empirical scoring system considering both intensity
and frequency in epithelial/lamina propria cells. In case
of cytoplasmatic proteins (APC, Caveolin, CBP, ERK,
HSP60, Cox2, C-myc, Cald1, DARPP32, MRE11A,
AndrogenR and EPS8), the score value was−2 for neg-
ative staining; 0 for weak, 1 for moderate and 2 for in-
tensive strong, diffuse cytoplasmatic immunostaining.
In case of nuclear proteins (cyclinA1, Top1), the score
value was −2 for a negative immunoreaction, 0 if the
ratio of immunopositive cells was under 2.5%, 1 for a
ratio between 2.5% and 5%, and 2 if positive cells were
more than 5%. In case of EGFR, a−2 score represents
negative staining, 0–1 represents weak-moderate cyto-
plasmatic staining, and 2 represents strong cell mem-
brane staining.
To measure the association of the two categorical
variables (group and score) contingency tables were
constructed and tested by Chi-square test. If the dif-
ference was statistically significant (p < 0.05), a more
detailed analysis was visualized on the basis of the
Pearson residuals. These results were summarized in
a graphical association plot [http://gap.stat.sinica.edu.
tw/Software/GAP].
2.5. Immunohistochemistry
After dewaxing, antigen retrieval was carried out by
microwave oven heating (at 750W) in citrate buffer for
20 minutes. Signal conversion was performed with
standard indirect immunoperoxidase reaction, where
diamino-benzidine was used as chromogen substrate
(Dako). For immunohistochemical labellings, Abgene,
Dako antibodies were used according to the description
of the manufacturer.
2.6. Affymetrix whole genome expression analysis
From the homogenised samples that were collected
and snap frozen in RNAlater, total RNA was extracted
using the RNeasy Mini Kit (Qiagen) according to the
manufacturer’s instructions. Quantity and quality of the
isolated RNA were tested measuring the absorbance
by agarose or capillary gelelectrophoresis using the
2100Bioanalyzer and RNA 6000 Pico Kit (Agilent Inc,
Santa Clara, USA). Biotinylated cRNA probes were
synthesized from 5–8 µg total RNA and fragmented
using GeneChip cDNA synthesis reagents, a sample
cleaning kit and the IVT Labeling Kit [http://www.aff-
ymetrix.com/support/downloads/manuals/expression
s2 manual.pdf – 1 version] according to the Affymetrix
instructions. Ten µg of each fragmented cRNA sam-
ple were hybridized onto HGU133 Plus2.0 arrays
(Affymetrix) at 45◦C for 16 hours. The slides were
washed and stained using a Fluidics Station 450 and
an antibody amplification staining method was ap-
plied according to the manufacturer’s instructions. The
fluorescent signals were detected by a GeneChip Scan-
ner 3000.
2.7. Statistical analysis
Quality control analyses were performed according
to the guidelines of The Tumour Analysis Best Practices
Working Group [19]. Scanned images were inspect-
ed for artifacts, percentage of present calls (> 25%)
and the degree of RNA degradation were evaluated.
Based on the evaluation criteria all biopsy measure-
ments fulfilled the minimal quality requirements. The
Affymetrix expression arrays were pre-processed by
gcRMA with quantile normalization and median polish
summarization. For feature selection linear models
combined with empirical Bayesian methods were
used [24].
2.8. Correlation analysis between Affymetrix and
protein array data
Based on the Swissprot ID of the antibody array
targets, Affymetrix IDs for 481 genes were assigned
by using the Netaffx database. One Affymetrix ID was
assigned to each protein. In case of several Affymetrix
IDs, the 3’ end probe set was preferred. The changes
in expression (M values) of both mRNA and protein
were plotted in a frame of reference, then correlation
analysis was performed. For the selection of the best
correlating pairs the distance of the pair from zero and
the size of their quotient were taken as a basis.
3. Results
3.1. Discrimination of normal and tumorous groups
(normal vs. Dukes B and D)
Tumorous groups were collectively compared to the
normal samples, and the list of differentially expressed
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Table 2
Top 20 significantly altered protein between normal and colorectal samples
Gene name SwissProt ID Biological function M value adj,P,Val
ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) P51965 protein degradation −1.319 0.002
sequestosome 1 Q13501 cell differentiation −1.044 0.005
KH domain containing, RNA binding, signal transduction associated 1 Q07666 cell proliferation −0.733 0.008
branched chain aminotransferase 1, cytosolic P54687 cell proliferation −0.719 0.008
protein phosphatase 1, regulatory (inhibitor) subunit 1B (dopamine and
cAMP regulated phosphoprotein, DARPP-32)
Q9NNW1 signal transduction −0.616 0.035
syntaxin 8 Q9UNK0 transport −0.541 0.029
plectin 1, intermediate filament binding protein 500kDa Q15149 cytoskeletal anchoring −0.478 0.005
nitric oxide synthase 1 (neuronal) P29475 cell-cell signaling −0.408 0.025
adenomatosis polyposis coli P25054 signal transduction −0.397 0.026
caldesmon 1 Q05682 muscle contraction −0.392 0.022
proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) Q12920 immune response 0.389 0.033
serine/threonine kinase 24 (STE20 homolog, yeast) Q9Y6E0 signal transduction 0.431 0.003
topoisomerase (DNA) I P11387 DNA topological change 0.435 0.008
thioredoxin-like, 32kDa O43396 apoptosis 0.474 0.001
guanine nucleotide binding protein (G protein), beta polypeptide 1 P04901 signal transduction 0.478 0.004
F11 receptor Q9Y624 inflammatory response 0.529 0.005
cyclin A1 P20248 cell cycle 0.543 0.002
nuclear mitotic apparatus protein 1 Q14980 cell cycle 0.571 0.004
CDC-like kinase 1 P21127 cell proliferation 0.578 0.003
heat shock 60kDa protein 1 (chaperonin) P10809 protein folding 0.635 0.004
genes was compiled (Table 1.) Between the two groups
(normal vs. CRC) 67 differentially expressed genes
were found. Based on their function, they can be clas-
sified into apoptosis (5), cell cycle regulation (7), tran-
scription regulation (4), DNA replication (4), molecu-
lar transport and cell adhesion (45) related genes. The
top 10 over- and underexpressed genes are functionally
classified in Table 2.
3.2. Discrimination of normal and Dukes B groups:
protein markers of early cancer progression
In group Dukes B, 22 genes were found to be
significantly altered from normal mucosa (Table 3).
Nine of them were underexpressed, while 13 showed
upregulation compared to normal. They were classi-
fied into the following functional groups: ubiquitin cy-
cle (1), signal transduction (8), meiotic recombination
(1), viral envelopment protein (1), cell proliferation
(1), mitosis (3), oxidoreductase and lyase activity (1),
transcription factor (1), unknown (1), DNA topological
change (1), cell motility (1) and transport (1). In some
samples, the presence of HPV-16 virus was detected,
but as it was not present in all samples, it was excluded
of further analysis.
3.3. Discrimination of normal and Dukes D groups
In group Dukes D, 25 genes were found to be
significantly altered from normal mucosa. Thirteen of
them were underexpressed, while 12 showed upregula-
tion compared to normal. They were classified into the
following functional groups: ubiquitin cycle (1), signal
transduction (7), viral envelopment protein (1), DNA
repair (3), RNA binding (1), cell proliferation (3), regu-
lation of translation (1), ubiquitinylation (1), transcrip-
tion factor (1), cell differentiation (2), cell cycle (1),
transport (2) and mitosis (1). The percentual change of
expression and the cell function of the identified genes
can be seen in Table 4.
3.4. Identification of progression markers
The following two strategies were applied for the
identification of progression markers. First, results
from Dukes B and Dukes D samples were directly com-
pared with each other. Second, data from separately
performed analyses were compared in order to deter-
mine how the expression of one gene altered already in
the early stage of disease changes in the late stage. Us-
ing the first method, 58 genes were identified between
the early and late stage CRC samples out of which 11
showed a significant expression alteration between the
two groups (Table 5).
Using the second method, the underexpressed genes
in Dukes D stage could be classified into three sub-
groups based on their expression status in Dukes
B stage. There were 8 genes in the first subgroup
(HPV-16, NEDD4, MRE11A, UBE2E1, EPHA4,
KHDRBS1, SQSTM1, PPP1R1B), that already showed
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Table 3
Significantly altered proteins between healthy colon and early stage cancer samples
Gene name Biological function SwissProt ID M value
1 ubiquitin-conjugating enzyme E2E 1
(UBC4/5 homolog, yeast)
Ubiquitin cycle, Ubiquitin-dependent protein catabolism P51965 −1.865995434
2 sequestosome 1 Response to stress, Ubiquitin binding, Endosome transport,
Intracellular signaling cascade
Q13501 −1.728747978
3 MRE11 meiotic recombination
11 homolog A (S. cerevisiae)
Meiotic recombination, Meiosis, Double-strand break repair
via nonhomologous end-joining
P49959 −1.5668813
4 HPV-16 L1 Viral envelopment protein P03101 −1.170942471
5 protein phosphatase 1, regulatory (in-
hibitor) subunit 1B (dopamine and cAMP
regulated phosphoprotein, DARPP-32)
Signal transduction, Protein phosphatase inhibitor activity, pro-
tein kinase inhibitor activity
Q9NNW1 −1.127870256
6 KH domain containing, RNA binding,
signal transduction associated 1
RNA binding, signal transduction Q07666 −0.99810321
7 branched chain aminotransferase 1,
cytosolic
Cell proliferation P54687 −0.759377286
8 EphA4 RNA binding, signal transduction P54764 −0.620030199
9 neural precursor cell expressed, develop-
mentally down-regulated 4
Structural molecule activity, Nuclear organization and biogen-
esis, Mitotic anaphase
P46934 −0.618087113
10 prenylcysteine lyase Oxidoreductase activity, Lyase activity Q9UHG3 0.501257698
11 thioredoxin-like, 32kDa Electron transporter activity, Thiol-disulfide exchange interme-
diate activity, Apoptosis, Signal transduction
O43396 0.514952034
12 casein kinase 2, beta polypeptide Wnt receptor signaling pathway, Protein serine/threonine ki-
nase activity
P13862 0.532917948
13 heat shock transcription factor 4 Transcription corepressor activity, Transcription factor activity,
Response to unfolded protein, Transcription, Protein folding
Q9ULV5 0.534018124
14 nuclear mitotic apparatus protein 1 Mitosis Q14980 0.54577123
15 polyamine-modulated factor 1 Q9UBQ3 0.551012235
16 cyclin A1 Mitosis, Regulation of cyclin dependent protein kinase activity P20248 0.557753319
17 epidermal growth factor receptor (ery-
throblastic leukemia viral (v-erb-b) onco-
gene homolog, avian)
Epidermal growth factor receptor signaling pathway, Negative
regulation of cell cycle, ATP binding, Transferase activity
P00533 0.564085732
18 CDC-like kinase 1 Cell cycle P21127 0.574731447
19 topoisomerase (DNA) I DNA topological change, DNA unwinding P11387 0.577033093
20 guanine nucleotide binding protein (G
protein), beta polypeptide 1
Signal transducer activity, G-protein coupled receptor protein
signaling pathway
P04901 0.60497692
21 F11 receptor Cell motility, Inflammatory response Q9Y624 0.698497879
22 heat shock 60kDa protein 1 (chaperonin) Unfolded protein binding, Mitochondrial matrix protein import P10809 0.776671019
downregulation in early stage CRC. Underexpressed
genes in Dukes D stage that showed no significant
downregulation in Dukes B stage (EIF4E, HSP90AA1,
AR, LCP2) formed the second subgroup. The only
gene in the third subgroup was ATP1B2, which was
slightly overexpressed in Dukes B stage.
Those genes that were overexpressed in Dukes D
stage were also classified into three subgroups. EGFR
and NUMA1 were in the first subgroup: they were al-
ready overexpressed in early stage of CRC. Genes that
were only slightly overexpressed in early CRC (CAV1,
TOP2B, EPS8, NPAT, STXBP1, SEMA4D) formed the
second subgroup. The third subgroup contained genes
that were overexpressed in Dukes D stage but underex-
pressed in Dukes B stage (GAP43, NCF2, POLE).
All genes that were underexpressed in Dukes B stage
were also underexpressed in Dukes D stage, and 9 of
the upregulated genes in early CRC were also overex-
pressed late stage CRC. In case of 4 genes (HSPD1,
TOP1, PMF1, HSF4), only protein levels increased
during disease progression, their gene expression,
however, was not altered.
3.5. TMA verification of antibody array results
3.5.1. Normal vs. tumour
The upregulation of TOP1, CCNA1 and HSP60, and
the downregulation of APC were validated by TMA. In
case of v-myc, the expression decrease detected by pro-
tein chip was significant (p = 0.019), but considerably
lower than the expression decrease validated by TMA
immunohistochemistry. In case of AR, the results of
the protein chip and TMA did not agree.
3.5.2. Normal vs. early stage CRC
Six genes (TOP1, HSP60, CYCA1, NUMA1,
CALD1, EGFR) were selected for TMA validation
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Table 4
Significantly altered proteins between normal mucosa and late stage colorectal cancer samples
Gene name Biological function SwissProt ID M value
1 ubiquitin-conjugating enzyme E2E 1 (UBC4/5 ho-
molog, yeast) (UBE2E1)
Ubiquitin cycle, Ubiquitin-dependent protein catabo-
lism
P51965 −1.3655365
2 sequestosome 1 () Response to stress, Ubiquitin binding, Endosome
transport, Intracellular signaling cascade
Q13501 −1.2216673
3 HPV-16 L1 P03101 −1.1267989
4 MRE11 meiotic recombination 11 homolog A (S.
cerevisiae)
Meiotic recombination, Meiosis, Double-strand break
repair via nonhomologous end-joining
P49959 −1.0716098
5 protein phosphatase 1, regulatory (inhibitor) sub-
unit 1B (dopamine and cAMP regulated phospho-
protein) (DARPP-32)
Signal transduction, Protein phosphatase inhibitor ac-
tivity, protein kinase inhibitor activity
Q9NNW1 −0.9386422
6 KH domain containing, RNA binding, signal trans-
duction associated 1
RNA binding, signal transduction Q07666 −0.8630941
7 heat shock 90kDa protein 1, alpha P07900 −0.8473879
8 eukaryotic translation initiation factor 4E RNA cap binding, Regulation of translation P06730 −0.7378523
9 androgen receptor Steroid binding, Cell proliferation, Regulation of tran-
scription, Protein dimerization activity
P10275 −0.7205401
10 neural precursor cell expressed, developmentally
down-regulated 4 (NEDD4)
protein degradation; protein ubiquitinylation. P46934 −0.6205902
11 EphA4 RNA binding, signal transduction P54764 −0.5975661
12 lymphocyte cytosolic protein 2 (SH2 domain con-
taining leukocyte protein of 76kDa)
Q13094 −0.5729652
13 ATPase, Na+/K+ transporting, beta 2 polypeptide P14415 −0.5413946
14 epidermal growth factor receptor pathway sub-
strate 8
SH3/SH2 adaptor activity, Cell proliferation, EGFR
signaling pathway, Signal transduction, SH3/SH2
adaptor activity
Q12929 0.5035487
15 growth associated protein 43 Cell differentiation, Regulation of cell growth, Neu-
rogenesis, Calmodulin binding
P17677 0.5042365
16 nuclear protein, ataxia-telangiectasia locus Q13632 0.5087894
17 epidermal growth factor receptor (erythroblas-
tic leukemia viral (v-erb-b) oncogene homolog,
avian)
Epidermal growth factor receptor signaling pathway,
Negative regulation of cell cycle, ATP binding, Trans-
ferase activity
P00533 0.5192014
18 DNA topoisomerase 1 Q 0.5367019
19 Rho GTPase activating protein 1 SH3/SH2 adaptor activity, GTP binding, Rho protein
signal transduction, Cytoskeleton organization and
biogenesis, Signal transduction
Q07960 0.5396524
20 syntaxin binding protein 1 Vesicle-mediated transport, Vesicle docking during
exocytosis
Q64320 0.5473203
21 caveolin 1 Scaffolding protein, molecular transporting P51636 0.5955298
22 sema domain, immunoglobulin domain (Ig), trans-
membrane domain (TM) and short cytoplasmic
domain, (semaphorin) 4D
Receptor activity, Neurogenesis, Anti-apoptosis, Cell
differentiation, Immune response
Q92854 0.5980394
23 nuclear mitotic apparatus protein 1 may be a structural component of the nucleus Q14980 0.6672197
24 polymerase (DNA directed), epsilon DNA binding, Nucleotide binding, DNA repair Q07864 0.6765401
25 neutrophil cytosolic factor 2 (65kDa, chronic gran-
ulomatous disease, autosomal 2)
P19878 0.7448919
from those genes that showed expression alteration
between normal and early CRC (Table 3). The elevated
expression of TOP1, HSP60 and CYCA1 could be ver-
ified by TMA. In case of NUMA1, the results of the
immunohistochemical analysis and the antibody array
did not agree. Caldesmon expression correlated sig-
nificantly with the AB array result, but its expression
was detected in stromal cells only. The overexpression
of EGFR was also validated in early CRC by both AB
array and TMA immunohistochemistry, its expression,
however, decreases with the progression of disease. In
Dukes D stage, its expression did not differ signifi-
cantly compared to normal according to both applied
methods.
3.5.3. Normal vs. late stage CRC
Comparing results from normal samples with Dukes
D stage samples, the following genes were exam-
ined with TMA: TOP1, AR, EPS8, CAV1, DARPP32
and NUMA1. According to TMA, TOP1 showed a
significant overexpression. In case of AR, an increased
expression was detectable by TMA, in contrast to our
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Table 5
Selected significantly differentially expressed genes during the tumor progression
Gene name Biological function SwissProt ID M value
ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) cell proliferation P51965 −1.314214341
sequestosome 1 signal transduction Q13501 −1.043584071
HPV-16 L1 transport P03101 −0.77024562
KH domain containing, RNA binding, signal transduction associated 1 cytoskeletal anchoring Q07666 −0.733015297
branched chain aminotransferase 1, cytosolic cell-cell signaling P54687 −0.718986189
protein phosphatase 1, regulatory (inhibitor) subunit 1B (dopamine and
cAMP regulated phosphoprotein, DARPP-32)
signal transduction Q9NNW1 −0.616086234
syntaxin 8 muscle contraction Q9UNK0 −0.541441325
F11 receptor immune response Q9Y624 0.528651479
cyclin A1 cell cycle P20248 0.542708779
nuclear mitotic apparatus protein 1 DNA topological change Q14980 0.571409175
CDC-like kinase 1 signal transduction P21127 0.577723106
heat shock 60kDa protein 1 (chaperonin) protein folding P10809 0.634592412
results by AB array. The TMA verification of EPS8,
CAV1, DARPP32 and NUMA1 failed, as there was no
significant change in immunohistochemical expression
between normal and late stage CRC.
3.5.4. Follow-up of tumour progression
Three genes that were found to be related to tumour
progression in our AB array analysis (CBP (EIF4),
ERK (MAPK12), v-myc), and 5 genes whose selec-
tion was based on literature data (GSTP, IGFR, TGFB,
CALD, COX2) but did not change significantly in this
study, were analysed by TMA.
ERK showed overexpression, while v-myc was un-
derexpressed. In case of CBP and EGFR, a tendency
of downregulation was detected between early and late
stage CRC. The results of TMA validation can be seen
in Fig. 2.
3.6. Validation results
Our results confirm recently published data,
according to which using only one marker is not
enough/sufficient for the classification of the different
stages of CRC. Therefore, we designed marker sets that
are appropriate for such classification.
To test the force of differentiation of the marker
sets, an additional, separate set of samples was exam-
ined by TMA analysis. Using cluster analysis based
on the score values, a set of 6 genes was determined
(CycA, Ar, Top1, TGFB, Hsp60, ERK), with which
discrimination between normal and tumorous groups
became possible (Fig. 3). This marker set was tested by
discriminant analysis. The distinction between normal
and tumorous groups was 100%, and 90.9% between
early and late stage CRC cases (Fig. 4).
3.7. Correlation between mRNA and protein array
results
Of the 500 genes examined, 465 (93%) showed no
expression alteration at protein level. Similarly, the
mRNA expression of these 465 genes showed no sig-
nificant change between normal and Dukes D stage
(groups). Both platforms detected the same expression
changes, which is visualized in Fig. 5. It can be seen
that higher oscillation is detected at mRNA than at pro-
tein level. A positive correlation was established in case
of 143 transcripts (R2 > 0,8), most of which belonged
to transport proteins. We also identified 95 genes whose
expression changed in opposite directions for mRNA
and protein levels (R2 > 0.9); the majority of these
genes is involved in the regulation of cell functions.
Next, genes with a highly significant expression al-
teration on both platforms were examined.
Twelve genes were identified (Fig. 6.) that showed
a significant difference between normal and Dukes
D stage CRC cases on both platforms. The absolute
values of their expression changes (M) was higher
than 0.5 on both platforms. These genes could be clas-
sified into 3 subgroups. In case of 4 genes (EIF4E,
AR, UBE2E1, EPHA4), mRNA underexpression was
followed by the downregulation of protein expres-
sion. These genes are involved in translation initiation,
transcription, intercellular communication, posttrans-
lational modification and signal transduction. The
second subgroup contained genes whose increase in
mRNA expression was followed by protein overex-
pression (NCF2, TOP2B, SEMA4D, NUMA1). These
genes are involved in cellular defense, electron carrier,
DNA topological change, immuneresponse, cell dif-
ferentiation and mitosis. In the third subgroup, mR-
NA expression and protein levels changed into opposite
directions (GLUL, GAP43, LCP2, PPP1R1B). These
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Fig. 2. Validation of selected protein markers on TMA. Protein expression of APC, Cyclin A, TOP1, EGFR. APC immunohistochemistry on
normal (1A), Dukes B (1B), Dukes B (1C) and Dukes D (1D) stage colorectal samples and the association plot (1E), showing the frequency of
the staining intensities. Cyclin A1 Immunohistochemistry on normal (2A), Dukes B (2B), Dukes B (2C), Dukes D (2D) stage CRC samples, and
the association plot (2E). Topoisomerase 1 immunohistochemistry on normal (3A), Dukes B (3B), Dukes B (3C), Dukes D (3D) samples, and the
related association plot (3E). EGFR immunohystochemistry on normal (4A), normal (4B), Dukes B (4C), Dukes D (4D) samples, and the related
association plot (4E).
genes are involved in metabolism, cell growth, cytokine
secretion and signal transduction regulation.
4. Discussion
Protein chips have been used in order to measure
changes in the expression of genes involved in sig-
nal transduction and to examine the activation status
of proteins. While further developing this technolo-
gy, however, the analysis of expression profiles is get-
ting more and more attention. Using reverse phase ar-
rays performed (RPA) on laser microdissected samples,
primary tumours were successfully discriminated from
their metastases based on the phosphoproteomics pro-
file of 29 genes involved in signal transduction [25]. It
is important to note that in previous AB array analyses
the number of genes showing a two-fold expression al-
teration was very low. Therefore, the intra-group vari-
ance expressed by the p value is more useful than the
exact values of expression changes.
Other studies also support that M values between
0.5–0.7 represent acceptable protein level changes.
In other words, the increase of protein expression to
140 percent, as well as its decrease to 70 percent, rep-
resent significant expression alterations [1].
The CCNE1 and CCND1 genes, which were found
to be significantly altered in our classification,have pre-
viously been reported to be overexpressed in colorectal
cancer. Higher levels of CCND1 have also been detect-
ed in the plasma of CRC patients. Our TMA-validated
AB array results support this observation.
The MRE11A gene codes a protein in the cell nu-
cleus that forms a complex with the RAD50 and NBS1
proteins. This complex is involved in homolog re-
combination, telomere protection and double stranded
DNA repair, hence it can be classified as belonging to
the MMR gene family [20]. Our antibody array data
agree with the results of Giannini et al. that MRE11
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Fig. 3. Hierarchical clustering of 6 differentially expressed genes found to be associated with CRC subtype after TMA validation.
is downregulated in colon cancer, probably due to its
mutation which results in a truncated protein. How-
ever, this observation made by AB array, could not be
validated by TMA as protein expression did not change
either in early or in late CRC.
Caldesmon 1 is expressed in low levels in colorec-
tal cancer (GeneAtlas), but it was recently reported
that this actin-binding protein plays a crucial role in
the invasivity of cancer cells [26]. Ectopic expression
of caldesmon 1 arrests extracellular matrix degrada-
tion, and decreases podosomes and invadopodia. The
examination of caldesmon 1 and related proteins may
be important in the assessment of tumour progression.
The case of caldesmon 1 highlights a special error
of AB arrays: tissue specificity of protein expression
and sample homogeneity may influence the results.
Caldesmon 1 is expressed mainly in smooth muscle and
stromal cells, in cell layers around the crypts, and not
in the epithelium. The M = 0.39 value measured by
AB array suggests that this protein is underexpressed in
tumours. However, immunohistochemistry shows that
this gene is highly overexpressed in some stromal cell
groups of tumours.
The opposing expression changes detected in this
study may be caused by a higher expression of the pro-
tein in the stromal parts of the tumour, but these his-
tological regions are relatively rare. It is also possible
that during sample collection, the healthy colon was
contaminated with smooth muscle. This renders the
validation of marker localization and tissue specificity
even more important.
Although association plots made according to the re-
sults of cluster and TMA analyses show no significant
molecular alteration between the two disease groups,
establishing a molecular-based disease classification
may be useful in order to complement conventional
clinical disease classification.
During tumour progression, some proteins showed
continuous overexpression (TOP1, HSP60), while
others (APC) were consistently downregulated in a
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Fig. 4. Discrimination of tumor subtypes. Discriminant analysis of colonic biopsy specimens. Note the clear separation of the single classification
groups based on the discriminatory genes detailed in the results section. Group 1 = normal, Group 2 = Dukes B colorectal cancer, Group 3 =
Dukes D colorectal cancer.
Fig. 5. Associations between mRNA and protein expression levels (A). The selected positively (B) and negatively (C) correlating genes.
trend-like manner. EGFR showed a stage-associated
expression, as in the phase of tumour growth it was
overexpressed, and after metastasis development, its
expression decreased.
Several different factors may help to explain the dis-
crepancies found between protein array and immuno-
histochemical analysis results. In some extreme cases,
antibody array and immunohistochemistry show oppo-
site results (e.g. MRE11A and AR). One of the most
important facts, which is also decisive in this study, is
the distinct antigen–antibody interaction between pro-
tein detection from protein extract and from FFPE tis-
sue. As observed in case of Caldesmon1, both the tis-
sue specific expression and the relative portion of tu-
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Fig. 6. The association between mRNA and protein products of 12 genes by M values of the two platforms. The first column (black) represents
the mRNA and the second column (gray) represents the protein expression.
mor cells may differ in tissue samples. Furthermore,
different antibodies were applied on the AB array and
the TMA-based immunohistochemistry. A further ex-
planation for the above mentioned discrepancies may
be tumor heterogeneity, because the crude extract for
the AB array was prepared from a relatively large tumor
tissue specimen, while TMAs contain only some 2mm
cores from the representative area of the FFPE tissue
sample. Another important fact is that each an-
tibody was individually optimized in TMA experi-
ments, while in case of AB microarray analysis sim-
ilar circumstances are provided for hundreds of an-
tibodies. In contrast to TMA evaluation, which is
based on discrete values and may have a subjective
component, continuous variables are objectively eva-
luted during array analysis. During TMA evalua-
tion (scoring) we focused only on the epithelial re-
gion. However, our experiences suggest that the dif-
ferent cell types in the tumor microenvironment may
affect protein array analysis causing the discrepan-
cies between the results of the two platforms. The
strong correlation between protein array and mRNA
may be explained by using the homogenized tissue and
microarray platforms. Considering these parameters,
the protein arrays may become useful tools for the as-
sessment of protein expression in diagnostic practice,
at present, however, immunohistochemical biomarker
detection on TMAs seems to be more reliable and cost-
effective.
To our knowledge, a similarly detailed study to de-
termine whether there is an association between mRNA
and protein expression has not been performed before.
According to our data and primarily because of the high
correlation values, it seems possible to predict protein
array results based on whole genome mRNA expres-
sion microarrays. These correlations may be increased
with the help of better protocols that allow the simulta-
neous isolation of RNA and protein in high quality and
sufficient amounts while using a single set of starting
material.
High throughput antibody arrays may be useful for
the identification of protein biomarkers and diagnostic
protein expression patterns. The identification of mark-
er combinations and their application in everyday prac-
tice are important tasks where antibody microarrays
may be of fundamental importance. As this technology
is extremely sensitive, these marker combinations may
be used in screening, diagnostics and follow-up of dif-
ferent stages of tumorous diseases. Today the number
of markers on antibody arrays is considerably lower
than the number of genes on whole genome mRNA
arrays although their price is higher. If a correlation
can be established between the results of whole genome
mRNA chips and antibody arrays of limited capaci-
ty, then the former may be used as a convenient high
capacity screening method before applying antibody
arrays that contain already planned targets. Based on
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our results, it seems that protein level changes can be
predicted by the results of mRNA expression analyses.
This could be important in case of proteins whose in-
tracellular concentration fluctuates rapidly. Because of
biological processes that are not yet fully understood,
such as stability, half-lifetime, RNA processing and its
regulation or posttranslational modifications, these re-
sults must be carefully evaluated. Taking these fac-
tors into consideration, antibody arrays may represent
a new approach for tumor and biomarker research.
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